The chosen example: antidepressant medication for depression

A biological treatment changes physiological processes to reduce the symptoms of a disorder. Here, the example is depression treated with selective serotonin reuptake inhibitors.

Major depressive disorder involves persistent depressed mood and/or loss of interest or pleasure, alongside other symptoms that cause significant distress or impair everyday functioning. Sleep may be disrupted; energy may fall, and concentration can become difficult. Treatment should improve the person's life, not just their questionnaire score.

How the treatment works

Selective serotonin reuptake inhibitors (SSRIs) are antidepressant medicines that inhibit the transporters which take serotonin back into the neuron that released it. The neurotransmitter Serotonin helps neurons communicate and is involved in processes including mood regulation.

Once serotonin has been released into the gap between neurons, some normally returns to the releasing neuron through reuptake. An SSRI reduces that removal. More serotonin is then available outside the neuron, altering signalling. The diagram shows this immediate action of the treatment; it does not give a complete explanation of depression.

Timing matters here. Reuptake inhibition starts relatively quickly, whereas substantial symptom improvement usually takes longer. Later adaptations in receptors and neural networks may contribute to the therapeutic effect. Calling an SSRI an instant mood switch is therefore misleading.

Successful treatment doesn't establish that a simple serotonin deficiency caused the depression, either. A change in a biological process can relieve symptoms without revealing the disorder's original cause.

How effective is it?

Treatment effectiveness describes how far an intervention produces meaningful improvements in the outcomes it is intended to change. For depression, we need to consider symptom reduction and recovery of everyday functioning, as well as whether improvement persists after treatment.

Controlled trials and evidence reviews generally find that, on average, SSRIs reduce depressive symptoms more than placebo. That average benefit does not mean every patient benefits. Estimates also vary with symptom severity, the outcome measures used and the study design. Some people improve substantially; others need a different treatment or a combination of approaches.

Where prescribing services are available, SSRIs can be comparatively accessible. Taking medication may also require less scheduled time than regular therapy sessions. But nausea, sleep disturbance or sexual side effects can make people less willing to continue treatment. Younger patients need particular monitoring for worsening mood or suicidal thoughts, especially early in treatment or after dose changes.

Adherence is the extent to which a person's behaviour follows an agreed treatment plan. If someone stops taking a medicine because of side effects, cost or a lack of perceived improvement, it cannot deliver its expected benefit. Stopping medication abruptly can also cause discontinuation symptoms, so withdrawal should be managed with the prescriber.

Judging the evidence

Comparing a medicine with placebo helps separate its effects from expectations and professional attention, as well as changes that would have happened anyway. Random allocation reduces systematic differences between groups, strengthening causal conclusions.

Blinding can weaken, though, if side effects reveal who received the active medicine. Short trials tell us less about long-term functioning and recurrence. The strongest judgement considers evidence of symptom improvement alongside tolerability and sustained benefit. It also asks how relevant the evidence is to the patients who will actually receive treatment.

The chosen example: cognitive behavioural therapy for depression

A psychological treatment uses psychological methods to change patterns of thinking, feeling or behaviour associated with a disorder. We will use the disorder from the previous section so that we can make a meaningful comparison between treatment approaches.

Cognitive behavioural therapy (CBT) is a structured psychological treatment that helps people identify and modify unhelpful patterns of thinking and behaviour. In depression, it targets processes that can maintain low mood. It doesn't assume that the person simply needs to think positively.

How the treatment works

Suppose someone receives a brief message from a friend and concludes, “They no longer want to spend time with me.” The person feels rejected and withdraws from social contact. With fewer opportunities for enjoyable experiences, the original interpretation becomes harder to challenge. Thoughts, emotions and behaviour can reinforce one another.

CBT helps the person interrupt this cycle. Together, the therapist and client examine the interpretation and consider alternative explanations. They agree on manageable actions that can provide new evidence. The cycle below shows a possible process that maintains depression, not an inevitable pattern in everyone with depression.

Cognitive restructuring is a therapeutic technique in which clients identify, evaluate and modify unhelpful interpretations. The client might separate the observable event—a short reply—from the conclusion that they are unwanted. They then weigh the evidence for that conclusion and develop a more balanced interpretation. Balanced doesn't mean artificially cheerful. It means better supported.

Behavioural activation is a therapeutic technique that increases engagement in meaningful or rewarding activities to counter patterns of withdrawal and avoidance. Rather than attempting an unrealistic schedule of major changes, a client might start with a brief walk or one planned conversation. Action need not wait until motivation has fully returned.

In sessions, the therapist and client commonly agree on goals and review what happened during practice between meetings. As treatment progresses, the client learns to recognize early warning signs and reuse these skills when difficulties return.

How effective is it?

Controlled trials and reviews provide evidence that supports CBT as a treatment for depression. It can reduce symptoms and improve functioning. Clients can also retain skills after therapy ends. Yet learning a skill is not the same as consistently using it: enduring benefits need to be measured, not assumed.

Attendance and opportunities to practise partly determine effectiveness, as do the therapist's competence and the quality of collaboration. Severe fatigue or concentration difficulties may make participation harder. Access matters too. A treatment may perform well in a research clinic but remain difficult to obtain because of waiting lists, fees or limited trained staff.

CBT may not adequately address every relevant influence on depression. Examining interpretations, for example, does not remove insecure housing or ongoing mistreatment. Good treatment distinguishes an inaccurate belief from a realistic concern, then adapts the plan accordingly.

Comparing treatments fairly

CBT and SSRIs both aim to improve symptoms and functioning, but their immediate mechanisms differ. CBT involves learning and practice; SSRIs directly alter physiological processes. They aren't necessarily competing choices. Combined treatment may be appropriate.

To compare treatments fairly, researchers need similar patients and must use the same outcome measures over comparable follow-up periods. A comparison of CBT with no treatment cannot establish that CBT is better than medication. Psychological treatment research also has a particular limitation: therapists and clients usually know which treatment they are receiving. Expectations and therapist allegiance can therefore influence outcomes, which makes independent assessment especially useful.

The chosen example: treatment of nicotine addiction

Nicotine addiction is a dependence-related health problem in which a person has difficulty controlling nicotine use and continues using it despite harmful consequences. These notes focus on addiction maintained through tobacco smoking. Successful treatment can also prevent future smoking-related illness, though treating an addiction is a different aim from preventing someone from starting.

The chosen strategy combines nicotine replacement therapy with behavioural support. Each component tackles a different obstacle to stopping smoking: withdrawal or established patterns of use.

How the combined strategy works

Nicotine replacement therapy (NRT) supplies nicotine without tobacco combustion, reducing withdrawal symptoms during a quit attempt. Patches release nicotine gradually. Products such as gum or lozenges can help manage cravings. Without combustion, the person avoids exposure to many harmful substances in tobacco smoke. Nicotine itself is not harmless, however.

Withdrawal refers to the physical or psychological symptoms that follow reduction or cessation of a substance once dependence has developed. With nicotine, these can include irritability, restlessness, difficulty concentrating and cravings. Easing the symptoms can help a person persist with a quit attempt.

Behavioural support is a structured intervention that helps a person develop and practise actions that support a health-related goal. For someone stopping smoking, this can involve agreeing on a quit plan. They may also anticipate situations associated with smoking and rehearse alternative responses. Someone who usually smokes during a work break might plan a short walk and arrange contact with a supportive colleague instead.

Together, the two components reduce withdrawal and help the person change routines and respond to smoking-related cues. Neither guarantees success. Treatment creates more favourable conditions for change, but those conditions still have to work in everyday life.

After the quit date, support gives the person a chance to adjust the plan. A brief return to smoking needn't be taken as proof that treatment has failed. It may instead reveal a situation that needs a different coping response. Continued follow-up matters: an initial quit attempt is not the same outcome as sustained cessation.

How effective is it?

Evidence reviews generally find that NRT improves smoking cessation compared with placebo or no NRT. Behavioural support can further improve outcomes. These findings support the combined strategy, but the size of the benefit depends on the comparison group, how treatment is delivered and the duration of follow-up.

Sustained abstinence from smoking is the most useful outcome—not attendance at sessions or an intention to quit. Researchers should state how they define abstinence and assess it after treatment has ended. Biochemical checks can support self-report, but the measure must fit the intervention. Cotinine indicates nicotine exposure; on its own, it cannot distinguish smoking from prescribed NRT use.

If unsuccessful participants are more likely to disappear from a study, loss to follow-up can make the results look overly favourable. Keeping participants in their originally assigned groups during analysis helps preserve the value of random allocation. Researchers must also explain how they handled missing outcomes.

Effectiveness beyond a research trial

Whether people can use the strategy depends on cost, a reliable product supply and access to support. Exposure to smoking at home or work may make quitting harder. Practical social support may make it easier. These factors influence treatment success; they are not reasons to blame the person receiving treatment.

Individual benefit and population impact are different. A successful programme that reaches very few smokers may prevent less illness overall than a somewhat less effective programme with broad uptake. Evaluation therefore needs to assess sustained cessation among participants and establish who can access and complete the intervention.